See All Slides - tctmd.com

Slides

Presentation TCT 2012

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

Presenter: David Kandzari

October 22, 2012

Presentation TCT 2012

AND, Should Also be Based on Hemodynamic Assessments: The Dimensionless AR Index

Presenter: Georg Nickenig

October 22, 2012

Presentation TCT 2012

Magnetic Resonance Imaging Guidance During Interventional Cardiovascular Procedures

Presenter: Robert Lederman

October 22, 2012

Presentation TCT 2012

Autologous vs. Allogeneic Cardiac Stem Cells: The Allstar Trial

Presenter: Raj Makkar

October 22, 2012

Presentation TCT 2012

Phase II and III Clinical Trials: Off and Running!

Presenter: Amit Patel

October 22, 2012

Presentation TCT 2012

Case Presentation with Discussion(7)

Presenter: Martinez Sepulveda

October 22, 2012

$PADN-1: Pulmonary Artery Denervation for the Treatment of Refractory Pulmonary Hypertension$

Presentation TCT 2012

PADN-1: Pulmonary Artery Denervation for the Treatment of Refractory Pulmonary Hypertension

Presenter: Shao Liang Chen

October 22, 2012

Presentation TCT 2012

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

Presenter: Dirk Sibbing

October 22, 2012

Presentation TCT 2012

“Nuggets” on Patient Selection After > 1,000 TAVR Cases (Performed and/or Proctored): Balloon-Expandable TAVR

Presenter: John Webb

October 22, 2012

Presentation TCT 2012

DES Clinical Outcomes Meta-analysis

Presenter: Sripal Bangalore

October 22, 2012

Advertisement

Slides

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

AND, Should Also be Based on Hemodynamic Assessments: The Dimensionless AR Index

Magnetic Resonance Imaging Guidance During Interventional Cardiovascular Procedures

Autologous vs. Allogeneic Cardiac Stem Cells: The Allstar Trial

Phase II and III Clinical Trials: Off and Running!

Case Presentation with Discussion(7)

PADN-1: Pulmonary Artery Denervation for the Treatment of Refractory Pulmonary Hypertension

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

“Nuggets” on Patient Selection After > 1,000 TAVR Cases (Performed and/or Proctored): Balloon-Expandable TAVR

DES Clinical Outcomes Meta-analysis

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content